Amryt Pharma Holdings Ltd
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$11.8M
Doctors Paid
3,101
Transactions
7,542
2023 Total
$3.0M
Payment Breakdown by Category
Royalty/License$8.0M (67.5%)
Research$2.8M (23.7%)
Consulting$366,980 (3.1%)
Food & Beverage$131,972 (1.1%)
Travel$84,510 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $8.0M | 16 | 67.5% |
| Unspecified | $2.8M | 1,663 | 23.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $394,314 | 152 | 3.3% |
| Consulting Fee | $366,980 | 115 | 3.1% |
| Food and Beverage | $131,972 | 5,297 | 1.1% |
| Travel and Lodging | $84,510 | 218 | 0.7% |
| Space rental or facility fees (teaching hospital only) | $30,750 | 16 | 0.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $16,104 | 4 | 0.1% |
| Grant | $15,000 | 1 | 0.1% |
| Charitable Contribution | $3,000 | 1 | 0.0% |
| Education | $984.98 | 59 | 0.0% |
Payments by Type
General
$9.0M
5,879 transactions
Research
$2.8M
1,663 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Double Blind, Randomised, Vehicle Controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa | $541,199 | 2 | 326 |
| MACRO Registry | $500,617 | 2 | 274 |
| A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With Partial Lipodystrophy | $425,543 | 0 | 96 |
| A 36-Month, Multicenter, Open Label Phase 4 Study to Evaluate the Immunogenicity of Daily SC Metreleptin Treatment in Patients With Generalized Lipodystrophy | $231,254 | 0 | 180 |
| LOWER: Lomitapide Observational Worldwide Evaluation Registry | $191,923 | 11 | 340 |
| MEASuRE: Metreleptin Effectiveness And Safety Registry | $186,422 | 0 | 235 |
| The variation of IGF-1 levels during administration of long-acting somatostatin receptor ligands (SRLs): association with time since injection and symptoms of acromegaly | $173,818 | 0 | 2 |
| OOC-AMC-302 | $147,447 | 10 | 19 |
| EASE | $141,247 | 1 | 72 |
| Clinical impact of anti-drug and neutralizing antibodies against metreleptin in patients with partial lipodystrophy | $64,305 | 0 | 2 |
| Metreleptin Effectiveness And Safety Registry | $52,135 | 0 | 92 |
| A phase II study of the efficacy of Oleogel-S10 (AP101) for the treatment of grade 2/3 radiation dermatitis in breast cancer patients | $40,400 | 0 | 1 |
| Esimating the Prevalence of CGL and FPL from Publically Available Exome Databases | $30,000 | 0 | 1 |
| Clinical impact of anti-drug and neutralizing antibodies against metreleptin in patients with partial lipodystrophy (HUM00196087) | $21,435 | 0 | 1 |
| A Randomized Phase II Study of The Efficacy of Oleogel-S10 (AP101) Gel for the Treatment of Grade 2/3 Radiation Dermatitis in Breast Cancer Patients | $20,200 | 0 | 1 |
| OOC-AMC-303 | $16,419 | 5 | 7 |
| A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS OF THREE ESCALATING DOSES OF MYCAPSSA | $10,058 | 4 | 14 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Anthony Heaney, M.d, M.D | Endocrinology, Diabetes & Metabolism | Los Angeles, CA | $124,671 | $0 |
| Wenyu Huang, M.d., Ph.d, M.D., PH.D | Internal Medicine | Chicago, IL | $67,258 | $0 |
| Dhaval Desai, M.d, M.D | Internal Medicine | Corona, CA | $67,086 | $0 |
| Elena Christofides, Md, Face, MD, FACE | Endocrinology, Diabetes & Metabolism | Columbus, OH | $66,144 | $0 |
| Philip Rabito, M.d, M.D | Specialist | New York, NY | $64,512 | $0 |
| Eliot Brinton, Md, MD | Endocrinology, Diabetes & Metabolism | Salt Lake City, UT | $51,475 | $0 |
| Adriana Ioachimescu, Md, MD | Endocrinology, Diabetes & Metabolism | Milwaukee, WI | $46,691 | $0 |
| Dr. Pamela Freda, M.d, M.D | Endocrinology, Diabetes & Metabolism | New York, NY | $36,475 | $0 |
| Dr. Anna Bruckner, Md, MD | Dermatology | Aurora, CO | $34,996 | $0 |
| Dr. Intekhab Ahmed, M.d, M.D | Internal Medicine | Philadelphia, PA | $34,640 | $0 |
| Dr. Ibrahim Amjad, M.d, M.D | Plastic Surgery | West Miami, FL | $27,862 | $0 |
| Tamer Yacoub, M.d, M.D | Endocrinology, Diabetes & Metabolism | Fall River, MA | $27,265 | $0 |
| Elif Oral, Md, MD | Internal Medicine | Ann Arbor, MI | $24,426 | $0 |
| Dr. Lisa Nachtigall, Md, MD | Internal Medicine | Boston, MA | $23,698 | $0 |
| William White, Md, MD | Hypertension Specialist | Farmington, CT | $17,950 | $0 |
| Joyce Teng, Md, MD | Dermatology | Palo Alto, CA | $16,915 | $0 |
| David Davidson, Md, MD | Internal Medicine | Bannockburn, IL | $16,718 | $0 |
| Lisa Myers, M.d, M.D | Endocrinology, Diabetes & Metabolism | Germantown, TN | $15,579 | $0 |
| Matt Marinkovich, Md, MD | Dermatology | Stanford, CA | $14,620 | $0 |
| Gregory Pokrywka, M.d. Facp, M.D. FACP | Internal Medicine | Kensington, MD | $14,537 | $0 |
| Dr. Kevin Yuen, Mbchb, Md, Frcp(Uk), MBCHB, MD, FRCP(UK) | Endocrinology, Diabetes & Metabolism | Phoenix, AZ | $13,907 | $0 |
| Daniel Halperin, Md, MD | Medical Oncology | Houston, TX | $13,000 | $0 |
| Dr. Emily Gorell, Do, DO | Pediatric Dermatology | Aurora, CO | $11,428 | $0 |
| Eliza Geer, Md, MD | Endocrinology, Diabetes & Metabolism | New York, NY | $10,970 | $0 |
| Christopher Cannon, Md, MD | Cardiovascular Disease | Boston, MA | $10,250 | $0 |
About Amryt Pharma Holdings Ltd
Amryt Pharma Holdings Ltd has made $11.8M in payments to 3,101 healthcare providers, recorded across 7,542 transactions in the CMS Open Payments database. In 2023, the company paid $3.0M. The top product by payment volume is JUXTAPID ($4.4M).
Payments were distributed across 90 medical specialties. The top specialty by payment amount is Endocrinology, Diabetes & Metabolism ($546,506 to 881 doctors).
Payment categories include: Food & Beverage ($131,972), Consulting ($366,980), Research ($2.8M), Travel & Lodging ($84,510), Royalties ($8.0M).
Amryt Pharma Holdings Ltd is associated with 3 products in the CMS Open Payments database.